For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
Kinetic profiling of RAS mutations with circulating tumor DNA - CO26
Purpose: In metastatic colorectal cancer (mCRC), RAS mutations drive resistance to anti-epidermal growth factor receptor antibodies. It is unclear whether RAS mutations ever become clonally undetectable.
The CCTG NE2 STOPNET neuroendocrine study has officially open in Canada. Researchers are investigating whether somatostatin analogues (SSA) are needed after targeted therapy for patients with neuroendocrine tumours.
“NE2 addresses an important question for patients and the healthcare system of whether we can reduce treatment burden by stopping SSAs after PRRT has been completed,” says Dr Jonathan Loree, the NE2 study co-chair and BC Cancer Oncologist.
The Canadian Cancer Trials Group (CCTG) at Queens University is currently seeking a visionary cancer trialist for the position of Senior Investigator (SI). The new SI will play a critical role for CCTG, acting as a co-principal investigator of numerous individual trials and a leader within the CCTG program and scientific committees.
As part of our commitment to promote capacity building in the Canadian cancer research landscape, the CIHR Institute of Cancer Research (CIHR-ICR), in partnership with the Ontario Institute for Cancer Research and Terry Fox Research Institute, as well as in-kind partners, the Canadian Cancer Society and Cancer Research Society, is pleased to announce the open call for applications for its annual Early Career Researcher (ECR) Workshop.
CCTG is thrilled to welcome Lindsay Clarke, who will be supporting the Genitourinary Disease Site Committee as a Patient Representative.
Lindsay Clarke is a registered nurse and mother who lives in Fort Saskatchewan, Alberta. She has a passion for caring for others and she has been volunteering with Prostate Cancer Canada (Cancer Canada) for the last 14 years. Prostate cancer is common amongst the men in Lindsay’s family, she tragically lost her father to prostate cancer in 2010, he was only 58 years old.
